Timothy Chafin, MD
Interventional Pain Medicine · Ahoskie, NCNPI 1336167733
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,343 of the $58,791 with a category attached, or 72.0%. Vertos Medical, Inc. accounts for 79.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $23,625 and has fallen 93.5% since, to $1,529 in 2025. Among interventional pain medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $228.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertos Medical, Inc.$47K
- Boston Scientific$5K
- Stryker$3K
- Vertiflex, Inc.$2K
- Spinal Simplicity, LLC$1K
- Painteq LLC$220
- plus $587 from 15 others
Across 107 payments — averaging $1148.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertos Medical, Inc.$116K
- Stryker$7K
What the payments were for
- Consulting fees$42,34372%
- Travel & lodging$8,29214%
- Food & beverage$8,15614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertos Medical, Inc. | 94 | $46,739 |
| Boston Scientific | 100 | $4,753 |
| Stryker | 4 | $3,106 |
| Vertiflex, Inc. | 10 | $2,343 |
| Spinal Simplicity, LLC | 8 | $1,044 |
| Painteq LLC | 6 | $220 |
| Collegium Pharmaceutical, Inc. | 14 | $163 |
| Abbott | 4 | $105 |
| GRT US Holding, Inc. | 1 | $58 |
| Si-bone, Inc. | 1 | $39 |
| Pfizer | 3 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| AstraZeneca | 2 | $25 |
| SPR Therapeutics, Inc | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Avanos Medical | 1 | $16 |
| Vertex | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mild Device Kit$47,276
- Superion ISS$2,052
- HA MINUTEMAN G3-R$976
- Superion Indirect Decompression System$974
- GENERAL - THERAPIES$947
- GENERAL PAIN MANAGEMENT$157
- PAINTEQ$103
How this compares
$58,791 in reported general payments places this provider in the 95th percentile of 45 interventional pain medicine providers in North Carolina.
See all interventional pain medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 65 | $36,583 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 200 | $5,414 |
| Fentanyl | 56 | $4,811 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 205 | $4,577 |
| Morphine Sulfate ErMorphine Sulfate | 77 | $2,710 |
| Lidocaine | 22 | $2,483 |
| Oxycodone Hcl | 111 | $2,089 |
| Pregabalin | 32 | $1,430 |
| Gabapentin | 114 | $1,429 |
| Tramadol Hcl ErTramadol Hcl | 13 | $1,042 |
| Tramadol Hcl | 172 | $974 |
| Naloxone Hcl | 12 | $824 |
| Diclofenac Sodium | 13 | $607 |
| Prednisone | 187 | $600 |
| Topiramate | 81 | $594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $163 | $36,58365 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 interventional pain medicine providers in North Carolina.
Other interventional pain medicine in Ahoskie
- Robert WilsonSalisbury$37K
- John MansfieldAsheville$25K
- Erin ChaneyJacksonville$22K
- Kevin CostelloGreenville$22K
- Scott JohnstonJacksonville$20K
- Harsh GovilStatesville$19K
- Troy GingerichCharlotte$19K
- Brent HarkriderNew Bern$14K
- Carey-Walter ClossonCharlotte$14K
- John HolderHampstead$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.